Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsAfter NVIDIA, Lilly Signs New AI Drug Discovery Deal with InsilicoInsilico Medicine partners with Eli Lilly in a potential $2.75B deal, combining generative AI and clinical expertise to fast-track development of next-generation oral therapies.Fact-Checked
Mergers & AcquisitionsNovartis to Acquire Excellergy for Up to $2 Billion, Adds Next-Generation Anti-IgE Antibody Exl-111Novartis will acquire Excellergy for up to $2 billion, gaining access to Exl-111, a next-generation anti-IgE antibody in Phase 1 designed to improve IgE suppression and expand treatment…Fact-Checked
Mergers & AcquisitionsOtsuka to Acquire Transcend Therapeutics in Up to $1.2B Deal to Advance PTSD Therapy TSND-201Otsuka has agreed to acquire Transcend Therapeutics for up to $1.225 billion, gaining TSND-201, a rapid-acting PTSD therapy that demonstrated significant symptom improvement in the Phase 2 IMPACT-1…Fact-Checked
Mergers & AcquisitionsBiogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Biologic DrugsBiogen has secured exclusive rights to develop subcutaneous formulations of two biologic drugs using Alteogen’s ALT-B4 hyaluronidase technology, in a partnership that could reach up to $579 million…Fact-Checked
Mergers & AcquisitionsJanux Targets 2026 TRACTr Updates, Announces BMS CollaborationJanux expects additional clinical updates for its TRACTr programs in 2026 while advancing a new partnership with Bristol Myers Squibb that could deliver up to $800 million in…Fact-Checked
Mergers & AcquisitionsMerck to Buy Terns, Strengthening CML Pipeline with TERN-701Merck will acquire Terns Pharmaceuticals for $6.7 billion to advance TERN-701, an investigational allosteric BCR::ABL1 inhibitor being studied in the Phase 1/2 CARDINAL trial for patients with chronic…Fact-Checked
Mergers & AcquisitionsAlnylam, Viz.ai Partner to Advance AI Detection of ATTR-CMAlnylam Pharmaceuticals has partnered with Viz.ai to develop an AI-powered care pathway aimed at improving early detection and coordinated management of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).Fact-Checked
Mergers & AcquisitionsGilead to Acquire Ouro Medicines for $1.7B; Galapagos in Talks to Partner on GamgertamigGilead Sciences has agreed to acquire biotechnology company Ouro Medicines for $1.675 billion upfront, with up to $500 million in additional milestones, to advance the BCMAxCD3 T-cell engager…Fact-Checked
Mergers & AcquisitionsSanofi Inks Up to $1.23B Licensing Deal for Kali Therapeutics’ Autoimmune Candidate KT501Sanofi has licensed Kali Therapeutics’ tri-specific T-cell engager KT501 for autoimmune diseases in a deal worth up to $1.23 billion, including $180 million upfront and near-term payments.Fact-Checked
Mergers & AcquisitionsSandoz Bets on $320B Biosimilar Opportunity with New Samsung Bioepis PartnershipSandoz and Samsung Bioepis have signed a multi-asset biosimilar deal covering up to five candidates, led by SB36 (vedolizumab), as Sandoz targets a $320 billion loss-of-exclusivity market with…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.